New Delhi, 15/9: There is good news about the ongoing vaccination in India. Russian vaccine Sputnik Light has got approval for Phase III bridging trial in India. The Drug Controller General of India (DCGI) has given a green signal to the trial of the vaccine on the Indian population. The Subject Expert Committee of DCGI had recently recommended the trial of Sputnik Light. Sputnik Lite is a single dose vaccine.
DCGI has given permission for Phase-3 bridging trial of Sputnik Light on Indians. Earlier in July, the Subject Expert Committee of the Central Drugs Standard Control Organization (CDSCO) had refused emergency use authorization to Sputnik Lite. CDSCO had called the local trial of the Russian vaccine necessary.
The committee found that the spuntal light was similar to the component-1 data of Sputnik V. Also, its safety and immunogenicity data in the Indian population had already been obtained in the trial. Dr Reddy’s Laboratory had signed an agreement with the Russian Direct Investment Fund (RDIF) last year for the Phase III trial of Spoontik V in India. A recent study published in The Lancet suggests that Sputnik Light has shown an efficacy of 78.6-83.7 percent against Kovid-19. This is more than many two-dose vaccine candidates. This study was done on at least 40 thousand elderly people in Argentina.
Comments are closed.